Integrate or isolate: Incorporating traditional safety-relat...

Should traditional safety considerations be treated as distinct from broader ESG frameworks, or fully integrated within them?

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

A practical route through regulatory uncertainty in clinical...

Organisations must remain agile and decisive across global portfolios, anticipating regulatory changes before they create clinical trial delays.

The reasoning problem

In R&D, decisions that matter most rarely happen during the documented steps; they happen in the pauses between them.

European launch: Manufacturing as cornerstone for success

In Europe, manufacturing may not make headlines in pharma partnering, but it’s one of the foundations on which strong partnerships must be built.

Patient population first: the strategy behind country decisi...